Netarsudil

Overview

A Rho kinase inhibitor with norepinephrine transport inhibitory activity that reduces production of aqueous As of December 18, 2017 the FDA approved Aerie Pharmaceutical's Rhopressa (netarsudil ophthalmic solution) 0.02% for the indication of reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Acting as both a rho kinase inhibitor and a norepinephrine transport inhibitor, Netarsudil is a novel glaucoma medication in that it specifically targets the conventional trabecular pathway of aqueous humour outflow to act as an inhibitor to the rho kinase and norepinephrine transporters found there as opposed to affecting protaglandin F2-alpha analog like mechanisms in the unconventional uveoscleral pathway that many other glaucoma medications demonstrate.

Indication

Netarsudil is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension .

Associated Conditions

Increased Intra Ocular Pressure (IOP)

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction	2025/07/24	NCT07082816	Not Applicable	Not yet recruiting	Alcon Research
The Effect of Topical Rho-kinase Inhibitors on Corneas of Patients With Fuchs Endothelial Corneal Dystrophy	2025/05/14	NCT06969586	N/A	ENROLLING_BY_INVITATION	University Hospital Dubrava
The Effect of ROCK Inhibitors on Corneas of Patients With Glaucoma and Pseudophakic Bullous Keratopathy (PBK)	2025/05/07	NCT06960629	N/A	ENROLLING_BY_INVITATION	University Hospital Dubrava
Effect of Rhopressa on Intraocular Pressure (IOP) in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Post-SLT	2025/03/07	NCT06865144	Phase 4	Recruiting	East Coast Institute for Research
Effect of Netarsudil vs Brimonidine in NTG Patients on Latanoprost	2024/06/10	NCT06449352	Phase 4	Recruiting	Westlake Eye Specialists
Next Generation Rocklatan	2024/06/04	NCT06441643	Phase 2	Not yet recruiting	Alcon Research
Efficacy and Safety Assessment of T4090 Ophthalmic Solution Versus Rhopressa® Ophthalmic Solution in Patients with Open-angle Glaucoma or Ocular Hypertension	2024/05/01	NCT06394973	Phase 2	Active, not recruiting	Laboratoires Thea
Topical Netarsudil for the Prevention of Proliferative Vitreoretinopathy in Patients with Retinal Detachment	2023/09/13	NCT06033703	Phase 1	Not yet recruiting	Massachusetts Eye and Ear Infirmary
A Multi-Center Study on the Use of Rho-Kinase Inhibitor to Reduce or Prevent PVR in RRD Eyes at High Risk for PVR	2022/12/21	NCT05660447	Phase 2	Active, not recruiting	Wills Eye
Rocklatan® Evaluation	2022/03/17	NCT05283395	Phase 4	Completed	Aerie Pharmaceuticals

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
Roclanda	Santen Oy,Niittyhaankatu 20,33720 Tampere,Finland	Authorised	1/7/2021
Rhokiinsa	Santen Oy,Niittyhaankatu 20,33720 Tampere,Finland	Authorised	11/19/2019
Rhokiinsa	Santen Oy,Niittyhaankatu 20,33720 Tampere,Finland	Authorised	11/19/2019

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
RHOPRESSA OPHTHALMIC SOLUTION, 0.02% w/v	Aerie Pharmaceuticals Ireland Limited	SIN16816P	SOLUTION, STERILE	0.02% w/v	7/4/2023
ROCKLATAN OPHTHALMIC SOLUTION, 0.02% W/V / 0.005% W/V	Aerie Pharmaceuticals Ireland, Limited	SIN16818P	SOLUTION, STERILE	0.02% w/v	7/4/2023

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Health Canada Drug Approvals

Approved Product	Company	DIN	Dosage Form	Strength	Market Date
No Health Canada approvals found for this drug.

CIMA AEMPS Drug Approvals

Approved Product	Company	Registration Number	Pharmaceutical Form	Prescription Type	Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product	Company	Registration Number	Dosage Form	Strength	Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name	MA Holder	MA Number	Pharmaceutical Form	Active Ingredient	Authorization Date
No UK EMC drug information found for this drug.

AI-Powered Research

Premium Access